Results 101 to 110 of about 2,368 (193)

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source

Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025

Eurosurveillance
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

JAMA Network Open
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Pelletier, Jonathan H., Rush, Sarah Z., Robinette, Eric, Maholtz, Danielle E., Bigham, Michael T., Forbes, Michael L., Shein, Steven L., Karsies, Todd J., Horvat, Christopher M.   +8 more
openaire   +2 more sources

Effects of Nirsevimab Introduction on Bronchiolitis and Respiratory Syncytial Virus in Catalonia

The respiratory syncytial virus (RSV) causes 70% of bronchiolitis cases and thousands of annual deaths, particularly in the paediatric population under six months, placing a significant burden on the public health system.
Valette Hohn, Berta
core   +1 more source

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

The Utilization of a Reference Guide to Promote Nurse Confidence in Providing Parental Education About Nirsevimab Vaccine

In July 2023, the FDA approved Nirsevimab (Beyfortus), a monoclonal antibody that provides direct protection to infants against respiratory syncytial virus (RSV), a dangerous respiratory virus that is the leading cause of infant hospitalization in the ...
Drabek, Allison A, Nowak, Julia, Kalasky, Audrey, Killich, Taylor   +3 more
core   +1 more source

Nirsevimab: a promising therapy for RSV

The Lancet Microbe, 2022
openaire   +1 more source

Mutational constraints on RSV F and its neutralization by antibodies. [PDF]

Nature
Simonich CAL, McMahon TE, Juviler G, Kampman L, Chu HY, Bloom JD.   +5 more
europepmc   +1 more source

Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review. [PDF]

Hum Vaccin Immunother
Razzini JL, Martinon-Torres F.
europepmc   +1 more source

Reply to Hodges et al. Comment on "Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. <i>Vaccines</i> 2026, <i>14</i>, 411". [PDF]

Vaccines (Basel)
Kura K, Lang JC, Wang D, Choi Y, Goveia MG, Sinha A, Chen YH, Elbasha EH.   +7 more
europepmc   +1 more source